Behcet's Disease

Introducing Our 2022-2023 VCRC-VF Fellow: Gözde Kübra Yardimci, MD

Gözde Kübra Yardimci, MD, began her one-year Vasculitis Clinical Research Consortium (VCRC)-Vasculitis Foundation (VF) Fellowship in July 2022 at Mount Sinai Hospital, University of Toronto, Ontario, Canada. Her main areas of interest at present are severe ischemic events in Takayasu arteritis and Behçet’s syndrome. Through her fellowship, Dr. Yardimci is…...

Read more

Positive Outlook Keeps Her Afloat in Journey with Behcet’s Disease

If Sarah Hewawitharana could be any other creature on this planet, there’s no question what it would be. The name she chose for her email address says it all: iwanttobeafish@. “I like it because it reminds me not to take life too seriously. I’ve always been obsessed with the water,…...

Read more

FDA Approves Otezla®for the Treatment of Oral Ulcers in Behcet’s Disease

Celgene Corporation announced on July 19 that the U.S. Food and Drug Administration (FDA) has approved Otezla® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behcet’s disease. Otezla, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only…...

Read more